Overview

A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary objective will be to compare the Eurofarma and Alenia formulations regarding their impact on the pulmonary function of mild to moderate persistent asthma patients and the secondary objective will be to compare the three study formulations regarding the clinical control of the symptoms and the patients' compliance to the treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Eurofarma Laboratorios S.A.
Treatments:
Budesonide
Formoterol Fumarate